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Starting with the epoch-making discovery of proinsulin, C-peptide has played an important interdisciplinary role, both as part
of the single-chain precursor molecule and as an individual entity. In the pioneering years, fundamental systematic experiments
unravellednewbiochemicalmechanismsandchemicalstructures.AftertheﬁrstdetectionofC-peptideinhumanserum,itquickly
becameamostusefulindependentindicatorofinsulinbiosynthesisandsecretion,ﬁndingapplicationinarapidlygrowingnumber
of clinical investigations. A prerequisite was the development of speciﬁc immuno assays for proinsulin and C-peptide. Further
milestoneswere:thechemicalsynthesisofseveralC-peptidesandtheaccomplishmentsinthesynthesisofproinsulin;thedetection
ofpreproinsulinwithitsbearingsonunderstandingproteinbiosynthesis;thepioneeringroleofinsulin,proinsulin,C-peptide,and
mini-C-peptides in the development of recombinant DNA technology; and the discovery of the enzymes for the endoproteolytic
processing of proinsulin into insulin and C-peptide, completing the pathway of biosynthesis. Today, C-peptide continues to serve
as a special diagnostic tool in Diabetology and related ﬁelds. Thus, its passive role is well established. Evidence for its active role in
physiology and pathophysiology is more recent and is subject of the following contributions.
Copyright © 2008 Dietrich Brandenburg. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
The discovery of proinsulin by Steiner and his coworkers.
([1], and references therein) not only opened the way to
understand the mechanism of insulin biosynthesisbut also
stimulated the development of the prohormone concept,
which was ﬁrst proposed by Givol in 1965 (see [2]). It was a
milestone in the elucidation of the biosynthesis of proteins.
As soon as the structure of proinsulin was known,
research developed along two interlinked lines: the intact
proinsulin parent molecule, and its “oﬀspring,” the con-
necting peptide or C-peptide. Proinsulin research proceeded
upstream towards the precursor, downstream towards con-
version, and in width, directed, for example, at various
species. Experimental work took place on all levels, from
in vitro studies on the subcellular scale to cells and tissues
to in vivo studies in animals. Very soon, the investigations
were directed towards man. Studies in healthy man and
patients gained increasing importance in diabetes research
and clinics. There were two aspects: C-peptide as an integral
part of proinsulin, and C-peptide as an individual entity.
Soon after the initial biochemical studies C-peptide began its
own, more and more independent life. Again, there were two
maindirections:C-peptideasadiagnosticmarkerindiabetes
mellitus, and C-peptide as a bioactive molecule. These
studies, based on the native molecule(s), were supplemented
by synthetic chemistry.
The literature on C-peptide is extensive. Figure 1,b a s e d
on a search in Medline, depicts the development in 5-year
intervals. In view of the large body of publications, this
historical review can only be very fragmentary. In particular,
while giving credit to individual scientists as far as possible,
full references will largely be restricted to selected reviews.
Since biological activity of C-peptide is the theme of this
special issue, this question will only be tapped.
2. THE FIRST DECADE 1967–1976
2.1. Thepioneeringyears
The successful chemical synthesis of insulin A- and B-chains,
and their combination to give biologically active insulin
preparations, was a milestone in peptide/protein science [2].






































Figure 1: Development of C-peptide publications.
separate chains raised again the crucial question: how is
insulin biosynthesis so eﬃciently accomplished by Nature?
It is now exactly 40 years, that the answer came through
the pioneering work of Don Steiner and Philip Oyer [3].
Labelling experiments with a human islet cell adenoma
lead to the discovery of a protein of molecular weight
10,800. Upon cleavage with trypsin, it yields insulin-like
material. The conclusion is “It is possible that this precursor
protein consists of a single polypeptide chain beginning at
its N-terminal end with the B chain sequence of insulin,
terminating with the A chain sequence, and bearing an
additional stretch of polypeptide between the normal chain
sequences.”
Subsequent experiments with human tissue and isolated
islets from rats elegantly show that the biosynthesis of the
precursor precedes the appearance of insulin, and the name
“proinsulin” is suggested for this protein [4].
In 1968, Chance et al. [5] isolate and characterise
proinsulin from crystalline porcine insulin. They elucidate
the amino acid sequence of a 33-peptide, which links the
insulin chains and is designated “connecting peptide.” Thus,
the ﬁndings and concept of Steiner are conﬁrmed and
extended, and all future work can now be based on solid
protein-chemical grounds. Figure 2 depicts the structure of
C-peptide and shows the sequence of human C-peptide.
Systematic followup studies in the laboratory of Steiner
et al. [4] quickly shed more light on the exciting ﬁndings.
Work is in two major directions, connected by many
factual and intellectual cross-links. Biochemical investi-
gations on the synthesis in in vitro systems, and iso-
lation/characterisation from available sources. Proinsulin
and C-peptide-like compounds are found as by-products
of crystalline porcine insulin and in commercial insulin
preparations; they can be detected in, and isolated from,
human plasma, urine, and pancreas.
The key question directed at the role of C-peptide is
answered in an impressive experiment: Steiner and Clark.
(1968, see [4]) can successfully demonstrate that fully
reduced proinsulin gives, upon reoxidation, high yields of
proinsulin. Thus, the primary role of proinsulin appears to
be to facilitate eﬃcient formation of the disulﬁde bonds of
insulin.
In the following year, it can be shown that two proin-
sulins are biosynthesised in the rat. The free connecting
segment of proinsulin can be detected and is named C-
(a) Schematic representation of human proinsulin. Drawing
based on Chance et al. [5]. B-chain (yellow) and A-chain
(green) are linked by C-peptide (red) via two pairs of basic
amino acid residues (blue)
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(b) Sequence of human C-peptide (31 amino acids, see [1])
Figure 2
peptide. It is found that about equivalent amounts of insulin
and C-peptide are secreted. C-Peptide can be isolated from
bovine and human pancreas, and the sequence of bovine
proinsulin is elucidated [4].
A most fruitful collaboration between the Departments
of Biochemistry and of Medicine has begun in Chicago, and
the biochemical studies are impressively extended towards
clinical diabetes research. Already in 1969, a diﬀerential
immunoassay with proinsulin and insulin antibodies is
developed by Rubenstein et al., See [6], and allows the
detection of C-peptide in human serum and plasma. The
authors consider a possible regulatory function of C-peptide
outside of the ß-cell.
On the chemical side, peptide scientists at Hoechst
Company succeed already in 1968 in the ﬁrst chemical
synthesisofporcineC-peptide(Geigeretal.[7]).Thepeptide
chain is assembled by synthesis in solution from several
fragments.
Subsequently, the emphasis is further shifting towards
studies in man. An important prerequisite is the availability
of methods for the unequivocal determination of C-peptide.
To this end, a speciﬁc radioimmunoassay is developed on the
basis of isolated human C-peptide and 131I Tyr-C-peptide.
Equimolar amounts of insulin and C-peptide are found
both in pancreas and in the circulation (Melani et al., 1970,
see [6]). Extended studies in humans show the presence
of C-peptide in the circulation of healthy as well as obese
persons and point towards the potential value of C-peptide
as independent indicator of beta cell function.
The availability of porcine proinsulin enables Lilly scien-
tists to carry out a number of experiments on the conversion
of the prohormone and the chemical as well as biological
and immunological characterisation of the resulting inter-
mediates (Chance, 1970, see [8]). First experiments towards
crystallisation and preliminary X-ray analyses of proinsulin
crystals are reported.Dietrich Brandenburg 3
In 1971, the 50th Insulin anniversary is celebrated in a
symposium in Indianapolis. It is the appropriate platform to
present and discuss the state of the art.
Intensive protein-chemical work of several groups, espe-
cially in Chicago and at Novo company in Denmark, on the
isolation and analysis of proinsulin and C-peptide results in
thepreparationofhumanC-peptide(Markussenetal.,1971)
and the determination of its sequence (Oyer et al., 1971, Ko
et al., 1971), the isolation of bovine C-peptide (Steiner et al.,
1971, Salokangas et al., 1971), and the conﬁrmation of its
sequence,asreviewedin[8].Arevisitofthesequenceofpork
proinsulin leads to a minor correction: Gln5→Glu.
In reﬁning studies on the proinsulin ⇒ insulin conver-
sion, a useful model for the converting enzyme system of
the ß-cell is worked out. The treatment in vitro of bovine
proinsulin with trypsin in combination with an excess of
carboxypeptidase B leads to intact insulin and C-peptide in
an essentially quantitative process (Kemmler et al., 1971, see
[9]).
3. THE NEXT FIVE YEARS 1972–1976
In the beginning, the primary structures of the C-peptides
of several other species are elucidated, as rat, horse, monkey,
sheep, and dog in Steiner’s laboratory, followed in 1973 by
the sequences of duck (Markussen & Sundby), and 1974 of
guinea pig C-peptide. In the same time, systematic studies
ontheconversionofproinsulintoinsulininisolatedratislets
andsubcelllularfractionsarecarriedoutandshedmorelight
on these processes (Kemmler et al., 1973, Tager et al., 1973)
For references, see Steiner et al. [9], Kitabchi [10].
In 1975/6, another milestone is set by Don Steiner
and his coworkers [11] with fundamental bearings for our
understanding of protein biosynthesis. Cell-free translation
experiments inislets ofratsorislet tumorsleadtogeneration
of a labelled protein of molecular mass of 11,500 daltons
with 23 additional amino acids NH2-terminal to the B-
chain sequence of proinsulin, which is named preproinsulin.
The N-terminal amino acid sequence of this hydrophobic
extension is NH2-X-Leu (Lys) Met-x-Phe-Leu-Phe-Leu-Leu
(Lys) Leu-Leu-x-leu- (Chan et al. [11]). The signal sequence
is rapidly cleaved. Signal peptide extension at/near the N-
terminus is later found in almost all secretory proteins
(animal, plant, bacteria), see [9].
With respect to the fate and role of C-peptide in the
organism, investigations in the rat deﬁne the kidney as the
main organ responsible for the degradation of proinsulin
and C-peptide (Katz and Rubenstein,1973 ,see [9, 10]). Very
careful and extended studies by Kitabchi on the possible
physiological function and activity of C-peptide under
variousconditionsareallnegative.Inconjunctionwithother
studies from the literature, it is concluded that the molecule
is devoid of activity [8].
This period is characterised by considerable activities
in peptide chemistry. The challenge of a total synthesis of
human proinsulin, which in those days meant the assembly
of all 86 amino acids in solution, is taken up in Japan and
Germanyin 1972/3 (seeNaithani etal.[12],andYanaiharaet
al. [13], and references therein). Several proinsulin peptides
are made, and a new synthesis of porcine C-peptide is
accomplished, shortly followed by the chemical synthesis
of human C-peptide in two laboratories. A considerable
number of peptides from human, porcine, and bovine C-
peptide are made, mainly for immunological purposes.
Modiﬁed C-peptides of human proinsulin have improved
properties for radioimmunoassay (see below).
The redox experiments of Steiner and Clark on the
formation of disulﬁde bridges between insulin chains had
clearly demonstrated the necessity for changing the bimolec-
ular process (as in chain combinations with separate chains)
into a monomolecular, intramolecular reaction. However,
the important question of chain length remained open.
Redox experiments with miniproinsulins give the answer.
They demonstrate that a short bridge of only 8 carbon
atoms can fully play the role of C-peptide and lead to
correct SS pairing in high yield (Brandenburg and Wollmer
[14]).TheseﬁndingsareconﬁrmedandextendedbyLindsay,
Geiger & Obermeier, and Busse & Carpenter, see [15].
In subsequent detailed studies on reduction/reoxidation of
proinsulin, Markussen & Heding (1973, 1975, see [16])
determine parameters for bovine proinsulin formation. The
studies with miniproinsulins pave the grounds for later
insulin production via minimal B-A connection [16].
In parallel to preparative chemistry, physical-chemical
studies in several laboratories between 1972–1976 aim
at obtaining information on the crystallisability, three-
dimensional structure, and conformation of proinsulin/C-
peptide (e.g., Pekar and Frank, 1972; Voigt and Wollmer,
1976, see [9, 10]).
Between 1973 and 1976, there is a considerable incr-
ease of immunological studies. Chemically synthesised C-
peptides, their derivatives, and fragments allow exploring
the immunological properties of human, porcine and bovine
C-peptide [12, 13], and the generation of various speciﬁc
antibodies for the development of immunoassays, particu-
larly RIAs, as tools for in vivo studies and analyses under
normal/disease conditions as well as tests for antigenicity.
Attachment of tyrosine to C-peptide allows later labelling
with 125-iodine, and hence synthetic human 125I-Tyr-C-
peptide [12] plays a special role as tailor-made tracer
molecule. An N-terminal derivative, human carbobenzoxy
(Z)-C-peptide, gives, after immunisation with albumin-
conjugated antigen, particularly high titers in guinea pigs
[17].
With the available tools of RIA, the number and extent
of experimental in vivo investigations and particularly of
clinical studies is rising. C-Peptide assays are used in a
large variety of studies, for example: on liver metabolism,
on ketoacidosis, in looking at infants of insulin-treated
diabetic mothers, in insulin-induced hypoglycemia, during
oral glucose tolerance test, or in comparing portal and
peripheral blood. Further studies extend to patients with
islet cell tumors or to the stimulation by OADs. Examining
children with juvenile diabetes, Ludvigsson and Heding [18]
ﬁnd that of 96 diabetic children, 35.4% had detectable
levels of C-peptide. For a detailed discussion of the clinical
signiﬁcance of circulating proinsulin and C-peptide see
Rubenstein et al. [19].4 Experimental Diabetes Research
4. THE SECOND DECADE 1977–1986
By 1977, major goals of fundamental research have already
been accomplished. For reviews, see Steiner “Insulin today”
[20] and Kitabchi [10]. C-peptide is now becoming an
ever growing factor in clinical research and diagnosis under
various conditions.
As seen in Figure 1, there is a steep rise in the number
of publications describing work concerned with C-peptide.
For the year 1977, PubMed yields 72 answers to “C-peptide
+ proinsulin,” of which about 43 = 60% concern a large
variety of studies which are based on the determination of
C-peptide in blood, plasma, or urine. Thus, besides limited
further work of a more fundamental nature, studies are
almost exclusively application directed, that is, making use
of the unique properties of C-peptide as an independent
indicator of beta cell function and insulin secretion under
normal and diabetic conditions.
The state of the art at the beginning of this decade
is summarised at three congresses: In 1978 the C-peptide
symposium in the USA and the symposium on proin-
sulin, insulin, and C-peptide in Tokushima, Japan, fol-
lowed in 1979 by the international symposium on insulin
and related hormones in Aachen, Germany. Experimental
work in chemistry and biochemistry has well advanced
and leads to remarkable achievements: the total chemical
synthesis of complete proinsulin from 16 fragments has
been accomplished in Japan, yielding a product with 10%
immunoreactivity (Yanaihara et al., 1979, see [21]). The
German competitors in Aachen succeed in synthesising the
twofragments1–45and46–86,spanningthewholesequence
of the prohormone [21]).
In biochemistry and molecular biology, the studies on
the proinsulin precursor succeed, in 1977, in the isolation
and characterisation of bovine preproinsulin from a cell-
free translation system and in 1978 in the detection and
identiﬁcation of preproinsulin in pancreatic islets (see [22]).
Again a new chapter of extreme importance and conse-
quences is being opened: recombinant DNA technology. As
in several cases before, insulin is assuming a pioneering role.
Although a two-chain molecule, it is the ﬁrst candidate to
be built up in E. coli via this revolutionary approach. First
detection of immunoreactive insulin [23] is soon followed
on the preparative scale [24]. While the approach via the
separate A- and B-chains and subsequent combination is
surprisingly eﬃcient, the proinsulin gene is the optimal
precursor [25]. Thus, besides human insulin for diabetes
treatment, human proinsulin and C-peptide become now
available in quantity for research and other applications.
Onlytwoyearslater,theprocessesaresuccessfullytransferred
to eucariontic cells (Lomedico et al., 1982, see [1]).
The application of C-peptide as a diagnostic tool dep-
ends critically on the availability of sensitive and selective
analytical methods. Although by 1976 progress has been
marked, the need for further development and reﬁnement of
immunological methods, in particular RIA, is considerable.
It is interesting to note that in 1977 not less than 5 papers
on the development of RIAs are published in Japan. Besides
other problems, the scarcity of antigen probes certainly is a
limiting factor. Since 1980, this obstacle is overcome through
the availability of biosynthetic human proinsulin and C-
peptide. Examples for immunological studies are a very
carefulstudywiththreeassaysystemsusingdiﬀerent antisera
by Kuzuya et al., 1978, see [26], aiming at the detection and
avoidance of pitfalls. Human proinsulin-speciﬁc antigenic
determinants can be identiﬁed by monoclonal antibodies
and allow hints towards the conformation of C-peptide
(Madsen et al., 1984, see [27]).
The advances in methodology as well as the results of
the large number of clinical studies between 1980 and 1986
are compiled in three reviews by Gerbitz [26], Polonsky and
Rubenstein [27]a sw e l la sF a b e ra n dB i n d e r[ 28]. Pitfalls
and limitations in the determination of the secretion and
hepatic extraction of insulin are discussed in [27]. The use of
peripheral C-peptide concentrations is considered as a valu-
able semiquantitative marker of beta cell secretory activity.
However,accuratequantiﬁcationismorediﬃcultandnotyet
possible. Conﬁrming earlier observations, it is stated that as
many as 15% of patients with type-1 diabetes retain life-long
beta cell function that persists at approximately 10% of that
observed in nondiabetic individuals [28].
5. THE THIRD DECADE 1987–1996
The investigations of the mechanism of biosynthesis lead to
another success. In 1990/1991, after long, extended search
in several laboratories, the enzymes responsible for the
endoproteolytic processing of proinsulin into insulin and C-
peptide are ﬁnally discovered. PC2, a 638-residue protein is
identiﬁed via a human insulinoma DNA by Smeekens and
Steiner (1990), and PC3 (PC1), a 753-residue protein, by
Smeekens et al., 1991. Both are serine proteases related to
subtilisin.AfterselectivecleavageattheC/AjunctionLys-Arg
or the B/C junction Arg-Arg, products with C-terminal basic
residues are generated. These residues are, as shown later,
ﬁnally removed by carboxypeptidase E, an exopeptidase. For
a detailed discussion, see Steiner [1, 29].
Clinical aspects of C-peptide as a diagnostic tool remain
in the centre, as documented by a large number of publi-
cations. For example, C-peptide is a valuable parameter in
the assessment of beta cell function in pancreas transplant
recipients, as reported by a Danish-Swedish Study Group in
1994 [30].
Since 1994, the question “does C-peptide have a phys-
iological role?” gains grounds and ﬁnds positive answers
in several directions [31]. By 1996, positive experimental
evidence is hardening, as new physiological eﬀects are
investigated. The conclusion is: C-peptide is a biologically
active hormone [32]. A negative aspect is the observation
that in vitro studies point towards a possible involvement
of C-peptide in the formation of amyloid-like ﬁbrils. It thus
may be of importance in the pathogenesis of amyloid in the
islets of Langerhans [33].
6. THE FOURTH DECADE 1997–2006
A very vivid portrait of C-peptide is painted by Don
Steinerinhisreview“TheproinsulinC-peptide—amultiroleDietrich Brandenburg 5
model” [1]. It summarises our knowledge from evolutionary
aspects to the role of C-peptide in processing from its
structure to analysis and clinical application. The latter
comprises, as before, the bulk of published studies in this
period.
A very substantial account of assays for insulin, proin-
sulin(s), and C-peptide available in 1999 is given by Clark
[34]. Further methodological advances aim now at over-
coming previous diﬃculties in accounting for the large dif-
ferences in metabolic clearance of C-peptide versus insulin.
Newly developed eﬀective methods for deconvolution of C-
peptide values allow widespread use of C-peptide assays for
evaluation of ß-cell function (Polonsky and O’Meara, 2001,
see [1]). Labelling with stable isotopes is proposed as a
new tool for in vivo pharmacokinetic and metabolic studies
[35]. The importance of C-peptide in the classiﬁcation of
diabetes mellitus, as well as its potential clinical applications,
is reviewed on the basis of a Medline literature search [36].
More studies are directed towards the biological activ-
ity of C-peptide. Based on observations with pancreas
transplants, the combined replacement of insulin and C-
peptide in diabetes treatment is deemed beneﬁcial [36]. Two
international symposia gather the experts and summarise
the state of the art: in 2000, “Cellular, physiological and
clinical eﬀects of C-peptide” in Detroit, Michigan, and in 2003
“Physiological and pathophysiological activities of C-peptide.”
Beyond the presentation of research results, the meetings
are aiming at the potential therapeutic value of C-peptide
replacement in preventing and ameliorating type 1 diabetic
complications and at identifying the immediate directions of
C-peptide research (see [37] and subsequent papers).
7. THE FIFTH DECADE 2007
At the beginning of the ﬁfth decade, clinical applications
continue to be the predominant ﬁeld; there is no new work
in chemistry or physical chemistry. C-peptide measurements
are compared in an international action in which 15
laboratories from 7 countries participate [38].
A very active area is stem cell research. C-peptide is again
a very useful marker of cell activity in exploring systems
and culture conditions. It has particular importance as an
independent indicator, because the source of insulin under
the conditions of cell culture is not always unequivocal [39].
Besides several studies with human or murine embryonic
stem cells, mesenchymal stem cells were investigated, for
example in [40]. Human umbilical cord blood-derived stem
cells can be engineered to engage in de novo synthesis
of insulin, as ﬁrst demonstrated by Denner et al. [41].
C-peptide is also a good independent marker for insulin
synthesis under the conditions of beta cell culture [42].
As demonstrated by insulin and C-peptide secretions,
beta cells occur naturally in extrahepatic bile ducts of mice
(Dutton et al. [43]). This discovery has signiﬁcance both
withrespecttoevolutionaswellasforregenerativemedicine,
pointing towards a new source of beta cells.
With respect to biological activity, new studies are
reported from John Wahren’s laboratory. Based on inter-
nalisation experiments, it is concluded that C-peptide has
properties of an intracrine peptide hormone (Lindahl et al.,
see[44].C-peptidetreatmentfor6monthsimprovessensory
nerve function in early-stage type 1 diabetic neuropathy, as
found in a study with 139 patients (Ekberg et al., see [44]).
The present stand is summarised by Wahren [44] “C-peptide
is a bioactive peptide.”
In clinical investigations, C-peptide serves as indicator
for beta cell function under therapy with an immunogenic
peptideDiaPep277fromthe60-kDaheat-shockprotein[45],
or treatment with thiazolidinediones, in testing the eﬀects of
dipeptidyl peptidase-4 inhibitors [46] and in a large study
on the incidence of diabetes in 2435 youths in the United
States [47]. Increased C-peptide levels, in conjunction with
other parameters, are found to be valuable indicators of risk
o fc o l o r e c t a lc a n c e r ,s e e ,f o re x a m p l e ,[ 48].
8. CONCLUSIONS
The history of proinsulin and C-peptide has been coined
and now over 40 years been intimately linked with their
discoverer, Don Steiner. The splendid original research by
him and his associates has been supplemented by excellent
reviews, which accompanied the experimental work and
reﬂected the state of the art as a red tape. Towards the end
of 4th decade, in 2005, Don Steiner was honoured by a
symposium on the occasion of his 75th birthday “Exploring
PancreaticBetaCell,InsulinBiologyandProteinProcessing.”
It gathered friends and researchers from all over the world,
and the programme of the Don Steiner Fest, held at the
University of Chicago, mirrored the scientiﬁc avalanche
triggered in 1967.
Based on exciting fundamental science, and beyond its
role as an integral part of proinsulin, C-peptide has quickly
found rising attention. The reason is its unique property as
anindependentmarkerofinsulinbiosynthesisandsecretion,
which makes it a special diagnostic tool in Diabetology and
related ﬁelds.
Progress depends on ideas, suitable methods, and ade-
quate tools. Such a tool is C-peptide. Proof of signiﬁcance
is simple and becomes obvious from the mere quantitative
look at the literature—the annual number of scientiﬁc
publications (see Figure 1). The steep rise beginning only 10
years after its discovery results in over 200 papers in 1984,
and from 1988 on to more than 300 per year.
While this passive role as diagnostic tool is now estab-
lished fora ratherlong time, the active role in physiology and
pathophysiology is more recent, and is a subject of current
andfutureresearch.Thiswillbereﬂectedinthecurrentissue.
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